CRONNasdaqMedicinal Chemicals & Botanical ProductsUS GAAP · USD

Cronos Group Inc.

Cronos Group Inc. is a cannabinoid company that develops, brands, manufactures, and distributes cannabis products for adult-use and medical markets. Its portfolio includes Spinach®, PEACE NATURALS®, LIT™, and Lord Jones®, and it operates through licensed production and distribution assets in Canada and Israel.

Liikevaihto147milj. USD
+24,6 %v/v
Liikevoitto (EBIT)−17,4milj. USD
+77,3 %v/v
EBIT-marginaali−11,9%
+53,2 %-yks.v/v
Nettotulos−9,4milj. USD
−123,0 %v/v
Vapaa kassavirta0,1milj. USD
−97,7 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−300−200−1000100200milj. USD2020: 47 milj. USD2020: EBIT −179 milj. USD20202021: 65 milj. USD2021: EBIT −292 milj. USD20212022: 87 milj. USD2022: EBIT −125 milj. USD20222023: 87 milj. USD2023: EBIT −85 milj. USD20232024: 118 milj. USD2024: EBIT −77 milj. USD20242025: 147 milj. USD2025: EBIT −17 milj. USD2025147−17
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Branded cannabis products45 %

Finished cannabis products sold under Cronos-owned consumer brands across adult-use and medical channels.

Canadian adult-use wholesale35 %

Sales to provincial cannabis control authorities and private-sector retailers in Canada.

Medical cannabis in Israel15 %

Licensed cultivation, distribution, and pharmacy-based medical cannabis products in Israel.

Supply and manufacturing services5 %

Third-party sourcing, contract manufacturing, and processing services supporting product availability.

Tuotteet

Raportoitu · osuus liikevaihdosta
74,0%25,7%FY2025100 %
  • Cannabis Flower74,0 %
  • Cannabis Extracts25,7 %
  • Other0,3 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Cronos sells primarily to government-controlled cannabis authorities, licensed retailers, and medical cannabis channels rather than direct mass-market consumers. In Canada, the main buyers are provincial cannabis control authorities and, in some provinces, private-sector retailers; in Israel, the company serves the regulated medical cannabis market through licensed distribution and pharmacy channels.

Canadian provincial cannabis control authorities

Buy wholesale cannabis products for provincial retail distribution and are the largest revenue source.

Canadian private-sector retailers and distributors

Purchase cannabis products for resale in provinces where private distribution is permitted.

Israeli medical cannabis market

Buys branded medical cannabis products through licensed cultivation, distribution, and pharmacy channels.

Licensed wholesale and international customers

Buy dried flower and other cannabis products for export or resale in select international markets.

Strategia

Cronos is focused on building branded cannabis franchises, expanding distribution, and improving supply chain efficiency while monetizing intellectual property. The company is also increasing production capacity, including the Cronos GrowCo expansion, to support domestic Canadian demand and international growth.

Brand portfolio expansionKeskipitkä aikaväli

Branded products can improve differentiation in a crowded cannabis market.

Global distribution networkKeskipitkä aikaväli

Broader channel access reduces reliance on any single country or buyer group.

Supply chain and capacity expansionLyhyt aikaväli

More reliable production and lower unit costs support margins and service levels.

Intellectual property monetizationPitkä aikaväli

Proprietary product development can create longer-term competitive advantages.

Maantiede

Q1/2026

Cronos is operationally concentrated in Canada and Israel, with principal facilities near Stayner, Ontario and licensed operations in Israel. The company also supplies select international markets, but its reported business is still anchored in regulated North American and Israeli cannabis regimes, which creates exposure to local licensing, import/export, and pricing rules.

Kanada56 %
Israel31 %
Other countries (US filing)13 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

Cronos faces regulatory, supply-chain, and market-structure risk because cannabis remains highly controlled and country-specific. The business also depends on a small number of large buyers, third-party suppliers, and agricultural production assets, which can create volatility in volumes, pricing, and margins.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Supply chain and agricultural disruption1Regulatory and licensing dependence2Competitive pressure and illicit market4Impairment of goodwill and intangibles5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Supply chain and agricultural disruptionVaikutus: KorkeaTodennäköisyys: Korkea

    Production depends on cultivation, third-party suppliers, and manufacturing partners.

    KohdistuuPeace NaturalsCronos GrowCoThird-party suppliers
  2. Regulatory and licensing dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Cannabis sales require country-specific licenses and compliance with changing laws.

    KohdistuuCanadaIsraelExport markets
  3. Customer concentrationVaikutus: Korkea

    A few provincial authorities account for a large share of revenue, limiting bargaining power.

    KohdistuuOntario Cannabis Retail CorporationAlberta GamingLiquorCannabis Commission
  4. Competitive pressure and illicit marketVaikutus: KeskitasoTodennäköisyys: Korkea

    Oversupply and illegal cannabis can reduce pricing and market share in adult-use channels.

    Kohdistuu: Canadian adult-use market

  5. Impairment of goodwill and intangiblesVaikutus: KeskitasoTodennäköisyys: Korkea

    Brand and reporting-unit values depend on future cash flow assumptions and market conditions.

    Kohdistuu: Lord Jones® and other acquired/intangible assets

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition

Wholesale cannabis sales and excise taxes can affect reported net revenue and timing.

Vaikutus: Affects quarterly comparability and gross margin presentation

Goodwill and indefinite-lived intangible impairment

Brand and reporting-unit values depend on future cash flow forecasts and market assumptions.

Vaikutus: Can create large non-cash charges if expectations weaken

Inventory valuation

Cultivation and processing businesses face obsolescence, yield, and cost-allocation judgments.

Vaikutus: Can materially affect cost of sales and gross profit

Fair value measurements

Valuation of acquired assets and reporting units uses discount rates, growth rates, and royalty assumptions.

Vaikutus: Influences impairment testing and acquisition accounting

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

Cronos Group Inc. (CRON) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo